RenalSense announced today that it raised $14 million to increase global commercialization efforts and advance its next-generation products. Jerusalem-based RenalSense develops the FDA-cleared and CE-marked Clarity RMS critical care monitoring system for the early detection of changes in renal function and acute kidney injury (AKI) risk, along with treatment monitoring. Clarity RMS has been installed […]
RenalSense
RenalSense’s urine flow monitoring system wins CE Mark
RenalSense today announced that it won CE Mark approval from its Clarity RMS system that monitors urine flow in critical care and perioperative settings. The Clarity RMS system continuously measures urine flow and automatically transmits real-time data and notifications of fluctuations to help with rapid intervention while monitoring treatment efficacy and fluid management. Jerusalem-based RenalSense […]